

0000
® 0000
0
00000
00

- 00000000000000000000
- 00000000000000000000
- 0000000000

00000000
 0000000000
 00000000
 0000000000
 00000000
 000000001
 01050mg
 04000000
 000000002
 00000000
 00100000
 0000000000
 00000000
 00000000
 00
 0000000000
 00000000
 000000001
 01
 037.5mg
 00000000
 00000000
 00000000
 000101
 050mg000
 00000

0000®
0000
0000
0000

000000000000

00000000
00000000
00
1.500000
00000000
00000000
000001
0500mg/m²
00000001
01050000
000000000
370000000
00010000
00000000
000
2.100000
00000000
00000000
000001
01,000mg/m²
00000001
00000101
00000000
00000000
00000000
00000000
000000010
0000
01,500mg/m²
00000000
000000

0000®
00
0000
0000
0000
0¹⁷⁷Lu00

0000000000000000000000

00000000
00000000
00000
0¹⁷⁷Lu000
01
07.4GBq
03000008
00000004
00000000
00000000
00000000
0000

000000002022030000

*1 Yao JC, Shah MH, Ito T, et al. N Engl J Med. 2011; 364: 514-523.
*2 Yao JC, et al. Lancet 2016; 387: 968-977.
*3 Rinke A, et al. J Clin Oncol. 2009; 27: 4656-4663.
*4 Fjällskog ML, et al. Cancer. 2001; 92050: 1101-1107.
*5 Kulke MH, et al. Dig Dis Sci. 2006; 51060: 1033-1038.
*6 Caplin ME, et al. N Engl J Med. 2014; 371030: 224-233.

□□□□□□□□□□□□□□□□

□□□□□□

Source URL: https://www.pro.novartis.com/jp-ja/products/afinitor/net/therapy_02